THE USE OF SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR 5 AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SUCH AS ALZHEIMER'S DISEASE AND LYSOSOMAL STORAGE DISEASES SUCH AS NIEMANN-PICK C DISEASE